Vivani Medical Inc. has announced promising results from their recent study involving an exenatide implant designed to reduce liver fat and manage body weight. The study, which was presented in a recent Form 8-K filing, demonstrated that the exenatide implant reduced liver fat by 82% in obese mice after 12 weeks. The findings were consistent with previous investigations using semaglutide injections. Additionally, the exenatide implant, delivered using NanoPortal™ technology, showed durable effects on body weight in healthy Sprague-Dawley rats over a period of 105 days, with some subjects observed for up to 112 days followed by a recovery period. These results highlight the potential of the exenatide implant in addressing obesity-related conditions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。